Summary

  • Payoneer recorded 224,985,441 votes for the merger agreement. That is about 66.40% of the 338,850,836 shares entitled to vote and 55,560,022 shares above the majority-of-outstanding approval floor.
  • Among the 227,276,269 votes counted as for, against or abstaining, support was about 98.99%. That is a useful participation statistic, but it is not the legal denominator for adoption.
  • Shareholder approval removes one closing condition. Eligible shares convert into the right to receive $7.40 only at the merger’s effective time, after the Delaware filing and the satisfaction or waiver of the remaining conditions.
  • Two New York complaints sought, among other relief, to enjoin the transaction. Payoneer voluntarily expanded the proxy disclosures while denying that the additions were material or legally required; the supplement did not change the price or prove that injunction risk had ended.
  • The remaining clock includes antitrust, foreign-investment and payments-licensing approvals, the absence of a legal restraint, an outside date in June 2027 and a specified regulatory extension to September 2027.

The vote should be read against all outstanding shares

Payoneer’s 14 September special meeting produced a decisive result. The company had 338,850,836 shares entitled to vote. The merger agreement received 224,985,441 votes in favour, 2,236,609 against and 54,219 abstentions. The affirmative count exceeded the 169,425,419-share majority floor by 55,560,022 shares.

Two percentages describe that result, and they answer different questions. Votes in favour represented approximately 66.40% of all outstanding shares. They represented about 98.99% of the votes counted on the proposal. The second figure captures the strength of support among participating shares; the first maps to the agreement’s adoption threshold. Calling this a “99% shareholder approval” without naming the denominator would turn a clean vote into an imprecise legal claim.

The distinction matters because an abstention did not help the proposal and non-voting shares remained inside the statutory denominator. Payoneer did not merely win a show-of-hands among those who appeared. It cleared a majority of the entire outstanding base. The shareholder condition is therefore no longer the uncertain part of the transaction.

That still leaves a category error to avoid. A vote authorises a contract. It does not execute every step of the contract.

Adoption, closing and effective time are separate events

The merger agreement establishes a sequence. First, Payoneer stockholders adopt the agreement. Next, the parties satisfy or waive the closing conditions that may lawfully be waived. At closing, the parties deliver the required documents and file a certificate of merger in Delaware. The merger becomes effective at the filing time or at a later agreed time stated in the certificate.

Only at that effective time does an eligible Payoneer share cease to be outstanding and convert automatically into the right to receive $7.40 in cash, without interest and subject to the agreement’s exclusions. Treasury shares, specified affiliated holdings and properly perfected dissenting shares do not follow the ordinary cash-conversion path. A holder who sells after the vote but before the effective time transfers the eventual right with the share.

This sequence is more than formalism. Before effective time, Payoneer remains a public company and its shares remain securities exposed to time, conditions and market judgement. After effective time, the surviving corporation becomes an indirect wholly owned Nuvei subsidiary and the ordinary eligible share becomes a payment right. The certificate of merger, not the vote tally, is the executable boundary.

The agreement has no financing condition, which removes one familiar source of buyer optionality. It does not remove the legal and regulatory conditions that the proxy enumerates. The analytical state after the vote is therefore “authorised but not effective”, not “completed”.

Supplemental disclosure is neither a price amendment nor an injunction ruling

The disclosure record developed on a different clock. Payoneer reported two New York Supreme Court complaints filed in August, by Kevin Turner and John Clark. The complaints alleged that the proxy omitted or misstated material information under New York common law and sought, among other remedies, to enjoin the transaction. Other demand letters asserted disclosure deficiencies or requested access to books and records.

Payoneer called the claims meritless. It nevertheless issued supplemental disclosures to moot disclosure claims and reduce the nuisance, cost and risk of litigation. The additions expanded the account of adviser relationships and financial analysis. They included information about the special committee’s adviser, links involving TCV and Advent, Davis Polk’s prior work for Nuvei or affiliates, and additional Qatalyst valuation detail.

The company also said that nothing in the supplement should be treated as an admission that the new information was material or legally required. That reservation is part of the evidence. It describes a tactical response to litigation, not a concession on the merits.

Three inferences would go too far. The supplement did not amend the $7.40 consideration. It did not itself dismiss the complaints or extinguish every books-and-records request. And it did not constitute a court order denying an injunction. Disclosure can narrow an omission theory or change the economics of pursuing it; only later procedural records can establish what happened to each claim.

This is the reality-layer distinction in a merger setting. A public filing changes the information set. A contractual amendment changes the bargain. A court order changes what the parties may execute. They can respond to the same dispute without being interchangeable.

Litigation is also a negotiated control surface

Transaction litigation is not managed by Payoneer alone. The merger covenant requires Payoneer to give Nuvei prompt notice and reasonable detail, keep Nuvei informed, allow it to participate at its own cost and consider its advice. Payoneer may not settle such litigation without Nuvei’s prior written consent, which cannot be unreasonably withheld, conditioned or delayed.

That allocation creates a joint operating surface before ownership transfers. Payoneer remains the defendant and continues to owe duties in its own corporate process. Nuvei has an economic interest in avoiding remedies, admissions or settlement terms that alter closing risk. The reasonableness qualification prevents consent from becoming an unlimited veto, but the buyer still has visibility and participation rights.

The disclosure supplement can be understood through that mechanism. It was a low-irreversibility intervention: more information was placed into the public record while the parties preserved the agreed consideration. A settlement, injunction, waiver or amendment would have a different legal and economic weight.

The regulatory perimeter now carries more of the timing risk

With the shareholder vote complete, attention moves to conditions that cannot be satisfied by another solicitation. The proxy describes antitrust and foreign-investment reviews as well as approvals connected to money-transmitter and payment-service licences. Payoneer operates a regulated cross-border payments network; the combination therefore crosses more than a conventional corporate-control review.

The closing condition also requires that no law, injunction or other order prohibit the merger. That is where litigation and regulation meet the effective-time clock. A disclosure claim may be weak on the company’s account and still consume time. A regulatory review may be routine in one jurisdiction and require a separate licence or ownership approval in another.

The agreement’s outside date is 12 June 2027. If specified regulatory approvals remain outstanding while the other conditions are satisfied or capable of being satisfied, it can extend automatically to 12 September 2027. The extension is a buffer, not a forecast. It shows where the parties allocated delay risk when signing.

The vote changes the termination map. Missing shareholder approval is no longer the live branch it was before 14 September. It does not disable termination rights tied to the outside date, a final legal restraint or other contractual failures. Nor does it guarantee that every condition will be cleared on the timetable management expects.

Four receipts, not one headline

The transaction can be followed with four documentary receipts.

The authorisation receipt is now available: the filed vote count, measured against all outstanding shares. The disclosure receipt is the supplemental filing, which identifies the claims and the information Payoneer added without changing the stated price. The condition receipt will appear through regulatory and court developments, including any orders, clearances, settlements or amendments. The execution receipt will be the certificate of merger and a filing stating that the effective time occurred.

Keeping those receipts separate protects analysis from two opposite mistakes. The first is premature certainty: treating shareholder approval as cash in the account. The second is manufactured alarm: treating a voluntary disclosure supplement as proof that the transaction terms were defective or that an injunction is likely. The filings support neither extreme.

What they support is a narrower, more useful conclusion. Payoneer obtained strong and legally sufficient shareholder authority. The price remains $7.40 for eligible shares under the existing agreement. The parties have responded to disclosure litigation without admitting material deficiency. Control still has to cross courts, regulators and Delaware effectiveness before the security becomes cash.

Sources